Related Experiment Video
Updated: Jun 16, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
The neurological toll of CAR T cell therapy
Meghan B Ward1, Giedre Krenciute1
1Department of Bone Marrow Transplantation and Cellular Therapy (BMTCT), St. Jude Children's Research Hospital, Memphis, TN, USA.
Abstract:
Understanding acute and long-term adverse events following CAR T cell therapy for cancer remains a crucial area of investigation as CAR T cells become more prominent in the clinic. In this issue of Cell, Geraghty and Acosta-Alvarez et al. investigate the mechanisms underlying cognitive decline in animal models following CAR T cell therapy for hematological, solid, and CNS malignancies.
Insights
Geraghty and Acosta-Alvarez et al. investigated cognitive decline after CAR T cell therapy in animal models. Their findings shed light on the mechanisms behind these adverse events, crucial for improving patient safety.
Area of Science:
- Immunology
- Neuroscience
- Oncology
Background:
- Chimeric antigen receptor (CAR) T cell therapy is a rapidly advancing cancer treatment.
- Adverse events, including neurotoxicity, require further mechanistic understanding.
- Cognitive decline is a significant concern following CAR T cell therapy.
Purpose of the Study:
- To investigate the mechanisms of cognitive decline after CAR T cell therapy.
- To explore these mechanisms across various cancer types (hematological, solid, CNS).
- To provide insights into managing CAR T cell-related neurotoxicity.
Main Methods:
- Utilized animal models to study CAR T cell therapy.
- Examined neurological and cognitive functions post-therapy.
- Analyzed underlying biological pathways involved in adverse events.
Main Results:
- Identified specific mechanisms contributing to cognitive impairment following CAR T cell administration.
- Demonstrated the impact of CAR T cells on cognitive function in preclinical models.
- Characterized the neurobiological consequences of CAR T cell therapy.
Conclusions:
- Understanding the mechanisms of cognitive decline is vital for CAR T cell therapy safety.
- These findings offer potential therapeutic targets for mitigating neurotoxicity.
- Further research is needed to translate these findings to clinical practice.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
